Anti-polyomavirus program
BK virus infection (e.g., nephropathy in transplant patients)
PreclinicalActive
Key Facts
Indication
BK virus infection (e.g., nephropathy in transplant patients)
Phase
Preclinical
Status
Active
Company
About Orthogon Therapeutics
Orthogon Therapeutics is a private, preclinical-stage biotech pioneering first-in-class antiviral therapies for polyomaviruses, a large family of ubiquitous viruses with no approved treatments. The company's core innovation is a drug discovery platform that precisely maps and targets protein-protein interactions, enabling the development of oral drugs against unconventional viral targets. With a leadership team experienced in antiviral drug discovery and startup exits, Orthogon has secured at least $14 million in funding to advance its lead program for BK virus in transplant patients while exploring broader applications in oncology and other diseases.
View full company profile